South Korea MFDS Medical Device Approval: The Complete Guide

Why South Korea Matters for Medical Device Companies

South Korea is the world's ninth-largest medical device market, valued at approximately USD 8 billion and growing steadily. It has one of the most sophisticated healthcare systems in Asia, with universal coverage, high adoption of advanced medical technologies, and a population that expects cutting-edge care. For medical device manufacturers looking beyond the US and EU, South Korea is often among the first expansion markets considered — and for good reason.

But South Korea's regulatory system is not a minor variation of the FDA or EU MDR. It is a distinct framework, administered by the Ministry of Food and Drug Safety (MFDS, formerly KFDA), with its own classification system, approval pathways, manufacturing requirements, clinical trial expectations, and language mandates. Manufacturers who assume they can repurpose their FDA or CE marking dossier with minimal adaptation routinely underestimate the time, cost, and complexity of Korean market entry.

This guide covers the full regulatory landscape: MFDS structure and authority, device classification (Class I through IV), approval pathways, Korean Good Manufacturing Practice (KGMP), the role of testing laboratories, clinical trial requirements, authorized representative obligations, MDSAP acceptance, IVD-specific requirements, reimbursement through HIRA, post-market obligations, recent regulatory reforms, and a direct comparison with FDA and EU frameworks. It is written for regulatory professionals at foreign manufacturers planning their first Korean submission — or those trying to understand why their current approach is not working.

MFDS: Structure and Authority

The Ministry of Food and Drug Safety (MFDS) is the national regulatory authority responsible for medical devices in South Korea. MFDS was reorganized and renamed from the Korea Food and Drug Administration (KFDA) in 2013 to reflect its expanded mandate and alignment with international regulatory standards.

MFDS is a cabinet-level ministry under the Prime Minister's Office. Within MFDS, the Medical Device Policy Division and the Medical Device Safety Bureau handle medical device regulation, including classification, premarket review, post-market surveillance, and Good Manufacturing Practice oversight.

Key MFDS functions relevant to medical device manufacturers:

• Premarket review and approval of medical devices and IVDs
• Classification of devices into risk-based categories (Class I through IV)
• KGMP inspections — both initial and periodic audits of manufacturing facilities
• Clinical trial authorization for devices requiring Korean clinical data
• Post-market surveillance including adverse event reporting, re-evaluation, and recall authority
• Standards development in collaboration with Korea Testing & Research Institute (KTR) and Korean Agency for Technology and Standards (KATS)

The primary legislation governing medical devices is the Medical Devices Act (Act No. 14328, as amended), along with its enforcement decree and enforcement rules. MFDS also issues notifications, guidelines, and technical standards that carry regulatory weight.

Important distinction: Unlike the FDA, which is part of a larger agency under the Department of Health and Human Services, MFDS operates as an independent ministry. This gives it broader authority and, in practice, a more centralized decision-making structure. Unlike the EU system, which relies on Notified Bodies for conformity assessment, MFDS itself directly reviews and approves devices (for Class II through IV). This means your regulatory relationship is directly with the government authority, not with a third-party body.

Device Classification: Class I Through IV

South Korea uses a four-tier, risk-based classification system. The system is conceptually similar to the FDA's Class I/II/III scheme and the EU's Class I/IIa/IIb/III framework, but with its own rules and a fourth class that raises the bar for the highest-risk devices.

Classification Overview

Class	Risk Level	Description	Examples	Regulatory Pathway
Class I	Lowest	Devices with minimal potential for harm	Tongue depressors, surgical drapes, manual surgical instruments, simple wound dressings	Notification (listing)
Class II	Low-moderate	Devices requiring some degree of regulatory control	Powered wheelchairs, ultrasound imaging systems, clinical thermometers, contact lenses, infusion pumps	Technical review and approval
Class III	Moderate-high	Devices with substantial risk requiring rigorous evaluation	Coronary stents, orthopedic implants, hemodialysis machines, ventilators, absorbable sutures	Technical review and approval (detailed)
Class IV	Highest	Devices that sustain or support life, are implanted, or present the highest risk	Cardiac pacemakers, heart valves, total joint replacements with novel materials, drug-eluting stents, deep brain stimulators	Technical review and approval (most rigorous)

How Classification Works

MFDS classification is determined by the device's intended purpose, duration of use, invasiveness, and potential risks. MFDS maintains a Medical Device Item Classification List — a comprehensive catalog that assigns each recognized device type to a specific class. This list is the definitive reference for classification.

If your device matches an existing item in the classification list, the classification is straightforward. If your device is novel and does not match any existing item, MFDS will determine the classification as part of the review process. Novel devices without a classification precedent are often assigned to Class III or IV by default until MFDS evaluates the risk profile.

Classification Comparison: South Korea vs. FDA vs. EU

South Korea	FDA	EU MDR
Class I	Class I (exempt or 510(k))	Class I
Class II	Class II (510(k))	Class IIa
Class III	Class II (510(k)) or Class III (De Novo/PMA)	Class IIb
Class IV	Class III (PMA)	Class III

This mapping is approximate. There are device types where the Korean classification diverges from both FDA and EU precedent. Do not assume your device will fall into the same relative risk class across all three jurisdictions.

Practical tip: Before initiating any Korean regulatory strategy, confirm your device's classification by consulting the MFDS Medical Device Item Classification List (available on the MFDS website in Korean, and partially translated in some industry databases). Misclassification derails timelines because the entire submission pathway, testing requirements, and clinical evidence expectations change with each class. If your device is novel, budget time for a pre-submission meeting with MFDS or your Korean Authorized Representative to discuss classification.

Approval Pathways

The approval pathway in South Korea depends entirely on the device class. The system is structured to provide proportional oversight — minimal requirements for Class I, progressively more rigorous review for Class II through IV.

Class I: Notification (Listing)

Class I devices are considered the lowest risk and require only a notification — essentially a product listing — with MFDS. This is submitted by the Korean License Holder (the manufacturer's Korean Authorized Representative or the manufacturer itself if it has a Korean legal entity).

Class I notification requires:

• Product name and description
• Classification code reference
• Manufacturer information
• Korean labeling
• Certificate of Free Sale from the country of origin (for imported devices)

Class I notifications are typically processed within 15 business days. No technical documentation review, testing, or clinical data is required.

Class II, III, and IV: Technical Documentation Review and Approval

All devices classified as Class II, III, or IV require formal MFDS approval through a technical documentation review process. The level of scrutiny increases with classification.

The approval application is submitted by the Korean License Holder and reviewed by MFDS or, for certain device types, by the Korea Testing & Research Institute (KTR) or other MFDS-designated review bodies.

Required Documentation

Document	Class II	Class III	Class IV
Application form	Required	Required	Required
Device description and intended use	Required	Required	Required
Principles of operation	Required	Required	Required
Raw materials and components list	Required	Required	Required
Manufacturing process description	Required	Required	Required
Performance and safety test data	Required	Required (more extensive)	Required (most extensive)
Electrical safety and EMC testing (for electrical devices)	Required	Required	Required
Biocompatibility data (for body-contact devices)	Required	Required	Required
Sterilization validation (for sterile devices)	Required	Required	Required
Software documentation (for software-containing devices)	Required	Required	Required
Clinical data or literature review	May be required	Required	Required
Risk management file (ISO 14971)	Required	Required	Required
Korean labeling and IFU	Required	Required	Required
Certificate of Free Sale	Required	Required	Required
GMP (KGMP) certificate	Required	Required	Required
Korean Authorized Representative agreement	Required (imports)	Required (imports)	Required (imports)

Review Timelines

MFDS has statutory review timelines, though actual timelines vary depending on whether additional information requests (deficiency letters) are issued.

Class	Statutory Review Period	Typical Actual Timeline
Class I	15 business days	2–4 weeks
Class II	60 business days	3–6 months
Class III	80 business days	6–10 months
Class IV	80 business days	8–14 months

The statutory review clock pauses whenever MFDS issues a deficiency letter and resumes when the manufacturer submits a response. For Class III and IV devices, multiple rounds of deficiency letters are common, which is why the actual timeline can significantly exceed the statutory review period.

Practical tip: Deficiency letters are the single largest source of timeline delays in Korean medical device approvals. The most common causes are incomplete test data, test reports not conforming to Korean standards, and language issues in the submission. Investing in a thorough gap analysis before submission — comparing your existing technical file against MFDS-specific requirements — consistently reduces deficiency rounds and total approval time.

Expedited Review Programs

MFDS has introduced several programs to accelerate market access for certain device categories:

• Innovative Medical Device Designation: Devices that use new technology not previously applied in medical devices may qualify for innovative device designation, which provides priority review, regulatory consultation, and reduced fees. This is conceptually similar to FDA's Breakthrough Device designation.

• Conditional Approval (Heo-ga): For urgent public health needs, MFDS can grant conditional approval with post-market commitments. This was used during the COVID-19 pandemic for diagnostic tests and ventilators.

• Fast-Track Review: Devices that address serious or life-threatening conditions with no adequate alternative may qualify for expedited review, which reduces statutory review timelines.

• Mutual Recognition of Foreign Approvals: MFDS has been moving toward accepting certain foreign regulatory decisions (particularly FDA clearances/approvals and CE certificates) as supporting evidence, though this does not eliminate the requirement for Korean review. It can, however, reduce the depth of technical documentation review for Class II devices with strong foreign regulatory history.

Korean Good Manufacturing Practice (KGMP)

Every medical device sold in South Korea — whether domestically manufactured or imported — must be produced in a facility that meets Korean Good Manufacturing Practice (KGMP) requirements. KGMP compliance is a prerequisite for obtaining MFDS approval.

KGMP Structure

KGMP is based on ISO 13485 but includes additional Korea-specific requirements. The KGMP framework is codified in the Regulations on Good Manufacturing Practice for Medical Devices issued by MFDS.

KGMP requirements are tiered by device class:

Class	KGMP Requirements
Class I	Basic GMP requirements — quality management system documentation, production controls, complaint handling. A KGMP audit is generally not required; self-declaration may suffice.
Class II	Full KGMP compliance including design controls, process validation, corrective and preventive action (CAPA), and internal auditing. KGMP audit is required.
Class III	Full KGMP compliance with additional emphasis on process validation for critical processes, supplier controls, and traceability. KGMP audit is required.
Class IV	Full KGMP compliance with the most rigorous audit scope, including detailed review of design controls, clinical risk management integration, and production process controls. KGMP audit is required.

KGMP Audit Types

MFDS defines four distinct types of KGMP audits, each triggered by different circumstances. Understanding which audit type applies to your situation is essential for planning and budgeting.

Audit Type	When Required	Description
Initial audit	First-time KGMP certification	Pre-approval audit of manufacturers for conformance with KGMP. Required before any Class II, III, or IV device can be approved. For foreign manufacturers, this almost always requires an on-site visit by Korean auditors.
Additional audit	Adding new product categories	When a manufacturer wants to add a new product category beyond what is already covered by an existing KGMP certificate. The scope is based on KGMP product categories defined by MFDS.
Change audit	Manufacturing site changes	Required when a KGMP-certified manufacturing site changes location, expands, reduces footprint, or undergoes other significant facility changes.
Renewal audit	Every 3 years	Mandatory renewal to maintain KGMP certification. The renewal application must be submitted at least 3 months before the current KGMP certificate expires.

KGMP Auditing Organizations

The auditing organization responsible for your KGMP audit depends on the device class. This is a detail many foreign manufacturers overlook — not all audits are conducted directly by MFDS.

• Class I (sterile and measuring devices only): KGMP audit is conducted by one of the six MFDS-designated third-party GMP review institutions.
• Class II devices: KGMP evaluation is performed by one of six MFDS-designated third-party GMP review institutions: KTL (Korea Testing Laboratory), KTR (Korea Testing & Research Institute), KTC (Korea Testing Certification), KXL, TUV SUD Korea, and TUV Rheinland Korea.
• Class III and IV devices: The six designated GMP review organizations and the Regional MFDS jointly conduct the review. For foreign manufacturers, this typically means a combined team of third-party auditors and MFDS officials conducting the on-site inspection.

Important distinction: Class I devices that are sterile or have a measuring function are subject to KGMP audit requirements even though general Class I devices are exempt. This catches many manufacturers off guard — if your Class I device is sterile (e.g., sterile wound dressings, sterile surgical drapes), you must obtain KGMP certification before marketing in South Korea.

KGMP Documentation Requirements

The documentation required for KGMP certification is extensive and falls into two categories: manufacturer-level documentation (demonstrating your overall QMS) and product-specific documentation (demonstrating the specific device's design and manufacturing controls).

Manufacturer-Level Documentation

Document	Description
GMP/MDSAP Certificate	Valid ISO 13485 certificate, preferably issued under MDSAP. Must be from an on-site audit by an approved certification body and cover the specific manufacturing facility exporting to Korea.
Audit Report with CAPA	Most recent MDSAP or ISO 13485 audit report, including documentation of corrective and preventive actions (CAPA) for any non-conformities identified.
Quality Manual	Complete and current version outlining QMS scope, exclusions, organizational structure, and responsibilities of key management personnel.
Standard Operating Procedures (SOPs)	Must include SOPs for control of records (document creation, revision, approval, retention), organizational responsibilities, traceability, and adverse event reporting.
QMS Inter-relationship Diagram	Visual representation showing how QMS elements interact — design, production, quality control, and post-market activities. Korean reviewers expect this specific document format.
Statement of QMS Correlation	Formal declaration showing how QMS processes relate to one another and comply with Korean regulatory expectations. Templates are typically provided by the Korean License Holder.

Product-Specific Documentation

Document	Description
Product List	Complete listing of models and product lines included in the KGMP application, forming the basis for scope determination.
Device Master Record (DMR)	Complete technical file including design drawings, specifications, quality assurance procedures, test methods, and acceptance criteria.
Instructions for Use (IFU)	Including safety warnings, usage guidelines, contraindications, and handling instructions. Must be in Korean.
Dimensional Drawings	Engineering diagrams with physical measurements, tolerances, and labeling locations.
Raw Material Specifications	Table listing all major components and raw materials, including material types, suppliers, and purpose — critical for demonstrating traceability and biocompatibility.
Manufacturing Process Flowchart	High-level diagram outlining each manufacturing step from material intake through assembly, testing, packaging, and sterilization (if applicable).
Packaging Information	Description of packaging materials and configuration, including unit size, sealing methods, and shelf life.
Product Label	Samples complying with Korean labeling regulations, including manufacturer, model, lot number, expiry date, and instructions in Korean.
Final QC Test Protocol and Report	SOPs detailing quality control steps before product release, plus batch records or final inspection results demonstrating compliance with specifications.
Sterilization Certificate and Report (if applicable)	Validation data showing effective sterilization, including method (EO gas, gamma, etc.), residual level analysis, and validation records.

Practical tip: Many Korean License Holders provide standardized templates for declarations, process charts, and inter-relationship diagrams. Using these templates improves alignment with MFDS reviewer expectations and reduces the risk of deficiency findings. Maintain a document readiness tracking spreadsheet — monitoring file names, version status, and review progress — to ensure completeness before submission.

KGMP Audit for Foreign Manufacturers

For foreign manufacturers (i.e., those manufacturing outside South Korea), the KGMP audit is conducted by MFDS or an MFDS-designated auditing body. Historically, this has required Korean auditors to travel to the manufacturing site — which added cost, scheduling complexity, and lead time.

Key points about KGMP audits for foreign manufacturers:

• Audit scope covers your quality management system, manufacturing processes, design controls, CAPA, complaint handling, and production environment — aligned with ISO 13485 requirements plus Korea-specific additions.
• Audit language is Korean. You will need a translator on site unless your staff speak Korean. MFDS auditors may have limited English proficiency.
• Audit duration is typically 2–3 days for a single product line, longer if you are seeking KGMP certification for multiple device families.
• Audit team composition for international audits typically involves a delegation of four Korean inspectors visiting the manufacturing facility. For Class III and IV devices, MFDS officials participate directly alongside the third-party auditors.
• KGMP certificate validity is typically 3 years, after which a renewal audit is required.
• Scheduling lead time for MFDS international audits can be 3–6 months, and longer in periods of high demand or travel restrictions.
• Key focus areas during audit that are not typically covered in the technical documentation review (TDR) process include sterilization process validation and the risk management file. Manufacturers should ensure these areas are audit-ready even if they have already passed the documentation review stage.

For importers representing multiple foreign manufacturers, MFDS applies a sampling approach: only one manufacturer may be subject to a full on-site audit, while the others undergo documentation review only. The sampling criteria consider product risk, import volume, and post-market surveillance data.

MDSAP and KGMP

This is a critical development. As of 2023, MFDS accepts MDSAP (Medical Device Single Audit Program) certificates as a substitute for KGMP facility audits for certain device classes. South Korea is not a full MDSAP member — it holds Affiliate Member status alongside Mexico (COFEPRIS), Argentina (ANMAT), Israel, Kenya, Taiwan (TFDA), and South Africa (SAHPRA). However, MFDS has entered into recognition arrangements and has been progressively accepting MDSAP audit results. In February 2024, MFDS published the MDSAP Audit Results Utilization Guideline (Guide No. 1349-01), formalizing the process.

In practice:

• If your manufacturing facility already holds an MDSAP certificate, you can use it to satisfy KGMP requirements, potentially avoiding a separate MFDS facility audit.
• The acceptance is not unconditional. MFDS may still require supplemental review or additional Korea-specific documentation depending on the device class and risk profile.
• MFDS also accepts ISO 13485 certificates from MFDS-recognized certification bodies as evidence of QMS compliance, though this typically does not fully replace the KGMP audit — it supplements it.

MDSAP Acceptance: Detailed Requirements and Limitations

The practical details of using MDSAP for KGMP are more nuanced than many summaries suggest. Based on current MFDS requirements:

• First-time KGMP only: Utilizing MDSAP during a KGMP audit is only applicable to manufacturers completing their initial KGMP certification. Renewal audits still require an on-site inspection.
• MDSAP report format: The MDSAP audit report must conform to the F0019.1 format specifically. Reports generated solely by the auditing organization (AO) in other formats will not be accepted.
• Non-conformity restrictions: The MDSAP audit report must demonstrate a clean compliance record. There cannot be any Grade 5 non-conformities, and no more than one Grade 4 non-conformity in Section 12 of the MDSAP report. If these thresholds are exceeded, MFDS will require a full on-site audit.
• Certificate validity alignment: If MFDS accepts the MDSAP audit results, the KGMP certificate validity will be tied to the expiration date of the MDSAP certificate — not the standard 3-year KGMP cycle.
• Success rate: In practice, the success rate for obtaining a paper-based (document-only) KGMP audit using MDSAP is approximately 50%. For manufacturers that have never undergone an MFDS audit, there is a near 100% likelihood that MFDS will require an on-site audit regardless of MDSAP status.
• Recognized Auditing Organizations: MFDS accepts MDSAP certificates from the recognized MDSAP AOs, which currently include BSI, DEKRA, DNV, DQS Medizinprodukte, Intertek, G-MED, NSAI, SGS, TUV Rheinland, TUV SUD, TUV NORD, and UL Solutions, among others.

Practical tip: If you already have or are pursuing MDSAP certification for other markets (Canada, US, Australia, Brazil, Japan), check whether your MDSAP certificate is accepted by MFDS for KGMP purposes. This can potentially eliminate the need for a separate Korean on-site audit for initial certification, saving 3–6 months and significant cost. However, do not assume it will be accepted — the ~50% acceptance rate means you should have a contingency plan for a full on-site audit. Ensure your MDSAP report uses the F0019.1 format and has a clean compliance record before applying. Discuss the specifics with your Korean Authorized Representative, as acceptance criteria evolve and vary by device class.

Testing Requirements: KTR and KOLAS-Accredited Labs

A significant portion of the Korean regulatory submission involves product testing — and South Korea has specific requirements about where and how testing is conducted.

The Dual Review Pathway: TDR vs. SER

Before discussing testing laboratories, it is important to understand the two distinct technical review pathways for Class II through IV devices, as the pathway determines the testing burden:

• Technical Document Review (TDR): Also called "General Technical File Review." This pathway applies to devices that are substantially equivalent to an already-approved product in Korea. TDR does not require clinical study reports. The review focuses on confirming that the device matches the predicate in structure, performance, and intended use, supported by appropriate test data.

• Safety and Efficacy Review (SER): This pathway applies to devices that are not substantially equivalent — those with new structure, new performance characteristics, new intended use, or newly developed technologies. SER requires a more comprehensive submission including clinical study reports and more extensive testing data.

For Class II devices, technical documents are reviewed by third-party review agencies (currently eight organizations designated by MFDS), not by MFDS directly. For Class III and IV devices, MFDS headquarters conducts the review directly.

Understanding which pathway applies to your device determines the scope of testing required, the review body, and the timeline. If your device can qualify for TDR through demonstrated equivalence to an existing approved device, the testing and documentation burden is significantly lower.

Korea Testing & Research Institute (KTR)

The Korea Testing & Research Institute (KTR) is a government-affiliated testing and certification organization that plays a central role in the medical device regulatory system. KTR is headquartered in Gwacheon, Gyeonggi Province, and has been designated by MFDS as a medical device testing and inspection organization pursuant to Article 29-4 of the Enforcement Regulations of the Medical Devices Act. KTR serves two distinct functions:

1. Product testing: KTR operates accredited laboratories that perform safety and performance testing for medical devices across all 24 recognized medical device item categories. For many device types, testing at KTR or a KTR-recognized laboratory is required or strongly preferred. KTR provides advisory support at no cost before formal test submission — a valuable resource for foreign manufacturers unfamiliar with Korean testing requirements.

2. Technical documentation review: For certain device classes and types, MFDS delegates the technical review of approval applications to KTR. In these cases, KTR acts as the review body, evaluating the submission dossier and making a recommendation to MFDS.

KTR Testing Capabilities and Process

KTR's medical device testing capabilities span the following areas:

• Electrical safety testing (IEC 60601-1 series, with Korean national deviations)
• Electromagnetic compatibility (EMC) testing (IEC 60601-1-2)
• Biocompatibility testing (ISO 10993 series)
• Sterilization validation (ISO 11135, 11137, 17665)
• Contact lens testing — KTR is the only organization in Korea that can conduct ultraviolet/visible light transmittance tests, oxygen permeability tests, and intraocular lens resolution/refractive tests for contact lenses
• Accelerated aging and shelf-life validation for setting device expiration periods
• Package integrity testing — physical safety of packaging and biological safety of the product
• Dental materials testing
• Software verification for medical device software and SaMD

To submit devices for KTR testing, the following documents are typically required:

1. Application form for test and inspection (KTR standard form)
2. Request for review including technical documents of the medical device
3. Physical samples for test and inspection
4. For pre-import samples: sample confirmation document, standard customs clearance report, and import declaration certificate
5. Existing test reports (if applicable, for gap assessment)
6. Other materials required for the specific test scope

KOLAS-Accredited Laboratories and Accepted Test Sources

The Korea Laboratory Accreditation Scheme (KOLAS), operated by the Korean Agency for Technology and Standards (KATS), accredits testing laboratories in South Korea in accordance with ISO 17025. For medical device testing, MFDS requires that test data be generated by one of the following:

• MFDS-registered laboratories — including KTR and other designated testing institutions (the default and most widely accepted option)
• IEC CB Testing Laboratories (CBTLs) — laboratories registered under the IECEE CB Scheme can issue CB Test Reports that MFDS accepts for electrical safety and EMC testing, provided they comply with Korean national deviations
• KOLAS-accredited laboratories in South Korea — accredited under ISO 17025
• GLP-certified laboratories — accredited according to OECD GLP rules, accepted for biocompatibility and toxicology testing
• Foreign laboratories recognized by MFDS or holding mutual recognition agreements — particularly those that are members of the International Laboratory Accreditation Cooperation (ILAC) Mutual Recognition Arrangement

TUV SUD Korea, for example, operates as both a third-party technical document reviewer for all Class II medical device categories and can issue IEC CB reports and GLP reports accepted for MFDS registration. This kind of dual capability — testing and review — can streamline the registration process.

Acceptance of Foreign Test Data

This is one of the most frequently asked questions from foreign manufacturers: "Can MFDS accept my existing test data?"

The answer depends on the test type and the issuing laboratory:

Test Type	Foreign Data Accepted?	Conditions
Electrical safety (IEC 60601-1)	Yes, in many cases	Must be from an accredited lab (ILAC MRA member or MFDS-recognized). Test report must comply with Korean standards, which are generally aligned with IEC but may have national deviations.
EMC (IEC 60601-1-2)	Yes, in many cases	Same conditions as electrical safety. Korean EMC standards may specify additional environmental parameters.
Biocompatibility (ISO 10993 series)	Yes, generally	Must be from a GLP-certified laboratory. MFDS follows ISO 10993 closely, but some test endpoint requirements may differ.
Sterilization validation	Yes, generally	Must be from an accredited laboratory. Korean standards are aligned with ISO 11135, 11137, and 17665.
Performance/functional testing	Case-by-case	MFDS may accept foreign performance data if the test protocols align with Korean technical standards. For novel devices or tests not covered by international standards, MFDS may require Korean lab testing.
Software verification and validation	Yes, generally	IEC 62304 compliance documentation is accepted. MFDS has specific software documentation requirements that must be addressed in addition to the IEC 62304 file.

In general, MFDS has become progressively more accepting of foreign test data, particularly from labs that are members of the International Laboratory Accreditation Cooperation (ILAC) Mutual Recognition Arrangement. However, there are device categories and specific Korean technical standards (KS standards) where only Korean-generated data is accepted.

Practical tip: Before initiating testing, have your Korean Authorized Representative confirm which tests MFDS will accept from your existing test reports and which require supplemental or new testing. Unnecessary re-testing is a waste of time and money. Conversely, submitting foreign test data that MFDS will not accept triggers a deficiency letter and adds months to the timeline.

Clinical Trial Requirements

Clinical data requirements in South Korea are risk-proportional, following the same logic as the classification system. Class I devices almost never require clinical data. Class II devices may require clinical literature reviews. Class III and IV devices frequently require clinical evidence, and for some high-risk devices, Korean clinical trial data is mandatory.

When Clinical Data Is Required

Class	Clinical Data Requirement
Class I	Not required
Class II	Literature review typically sufficient; clinical trial data rarely required
Class III	Clinical data required — may be satisfied by literature review, foreign clinical trial data, or Korean clinical trial data depending on the device
Class IV	Clinical trial data almost always required — MFDS may require Korean clinical trial data for novel or high-risk devices

Acceptance of Foreign Clinical Data

MFDS will accept foreign clinical data (e.g., data from US or EU pivotal trials) in many cases, particularly if:

• The clinical investigation was conducted in accordance with ISO 14155 or equivalent (e.g., FDA's IDE regulations)
• The study population is relevant to the Korean patient population (MFDS may raise questions if the study population has minimal Asian representation)
• The study endpoints align with Korean clinical practice standards
• The data was generated at sites with appropriate ethics committee (IRB) oversight and regulatory compliance

For some device categories, however, MFDS requires Korean clinical trial data — meaning a clinical investigation must be conducted at Korean clinical sites, with Korean patients, under Korean IRB oversight, and with MFDS approval of the clinical trial protocol. This is particularly common for:

• Novel implantable devices (Class IV)
• Devices where clinical outcomes may differ across ethnic or demographic groups
• Devices where Korean clinical practice differs substantially from Western practice
• First-in-class technologies without substantial foreign clinical evidence

Conducting a Clinical Trial in South Korea

If Korean clinical data is required, you must obtain Investigational Device Exemption (IDE) approval from MFDS before starting the trial.

Clinical Trial Approval Process

1. Institutional Review Board (IRB) approval from each participating clinical site
2. Clinical trial protocol submitted to MFDS for review — protocol must include study design, endpoints, sample size justification, statistical analysis plan, informed consent document, and investigator's brochure
3. MFDS review and approval — typically 30 business days for the initial review, though deficiency letters can extend this
4. Trial conduct — must comply with Korean Good Clinical Practice (KGCP), which is based on ICH-GCP (E6(R2)) with Korean-specific additions
5. Monitoring and reporting — adverse events must be reported to MFDS and IRBs per Korean regulatory timelines
6. Final clinical study report submitted as part of the device approval application

Clinical Trial Infrastructure

South Korea has excellent clinical trial infrastructure. Major academic medical centers — Samsung Medical Center, Asan Medical Center, Seoul National University Hospital, Severance Hospital (Yonsei), and others — have extensive experience running medical device trials. Korean investigators are familiar with international trial standards, and patient recruitment is generally efficient due to the country's dense, well-connected healthcare system.

However, the cost of Korean clinical trials has increased in recent years, and competition for investigator time at top-tier sites is intense. Budget accordingly and engage clinical sites early.

Practical tip: If you anticipate needing Korean clinical data, factor this into your global clinical strategy from the beginning. Running a multi-regional clinical trial that includes Korean sites from the outset is far more efficient than conducting a separate Korea-only trial after your US or EU studies are complete. MFDS is increasingly open to accepting data from global multi-regional trials that include Korean sites.

Korean Authorized Representative (License Holder)

Foreign manufacturers cannot directly register medical devices with MFDS. You must work through a Korean License Holder — either a Korean Authorized Representative (KAR) or by establishing your own legal entity in South Korea.

Role of the Korean License Holder

The Korean License Holder is the legal entity that holds the medical device license (approval) issued by MFDS. This entity is responsible for:

• Submitting the device approval application to MFDS
• Holding the MFDS license and maintaining it (including renewals and amendments)
• Korean labeling compliance
• Adverse event reporting to MFDS
• Post-market surveillance activities in Korea
• Communication with MFDS on behalf of the foreign manufacturer
• Import and distribution compliance (or working with a separate Korean distributor)
• Maintaining records required by Korean law

Options for Foreign Manufacturers

Option	Description	Pros	Cons
Korean Authorized Representative (KAR)	A Korean company that holds the license on your behalf	Lower cost, faster to set up, no need for Korean legal entity	License is held by the KAR (not you), dependency on third party, potential IP and commercial control issues
Own Korean subsidiary	Establish a Korean legal entity (branch office or subsidiary)	Full control over license, IP protection, direct MFDS relationship	Higher cost, requires Korean business registration, ongoing corporate compliance, local staff
Korean distributor as license holder	Your Korean distributor also serves as the license holder	Combines distribution and regulatory functions	Strongest dependency — if you change distributors, you may lose your MFDS license

Critical Consideration: License Ownership

This is perhaps the most important strategic decision for foreign manufacturers entering South Korea. Whoever holds the MFDS license effectively controls your market access. If your KAR or distributor holds the license, and you terminate the relationship, the license does not automatically transfer to you or your new partner. You may need to re-register the device, which can take months.

Some manufacturers address this risk contractually — requiring the KAR to transfer or surrender the license upon termination. However, enforcement of such clauses under Korean law can be complex. The safest approach, if your Korean business justifies the investment, is to establish your own Korean legal entity and hold the license directly.

Practical tip: Negotiate license ownership and transfer rights carefully before engaging a Korean Authorized Representative. Get legal advice from a Korean lawyer experienced in medical device regulation. The upfront cost of proper legal structuring is trivial compared to the cost of losing market access because your license holder refuses to cooperate during a business transition.

Korean Language Requirements

South Korea has strict language requirements for medical device regulatory submissions and product labeling. This is one of the most underestimated aspects of Korean market entry and is a leading cause of submission deficiencies and timeline delays.

Submission Documents

All documents submitted to MFDS for device approval must be in Korean. This includes:

• Application forms
• Device descriptions and intended use statements
• Performance and safety test data summaries
• Clinical data summaries
• Labeling and Instructions for Use
• Risk management documentation summaries

Foreign-language source documents (e.g., English test reports) can be submitted as supporting attachments, but the primary submission documents and summaries must be in Korean. Test reports from accredited foreign labs are generally accepted in English if accompanied by a Korean-language summary of the key findings. Some documents may be submitted in dual-language format (Korean and English side by side), which can help with technical accuracy review, but the Korean text is the legally binding version.

Translation Quality and Specialized Requirements

Korean medical device translation is a specialized discipline that requires translators with expertise in both regulatory terminology and the specific device technology area. Key considerations:

• Regulatory terminology alignment: Korean regulatory terms do not always correspond one-to-one with English equivalents. MFDS uses specific Korean terminology in its regulations and guidelines, and submissions must use these exact terms. A general Korean translator without medical device regulatory experience will likely use incorrect terminology.
• Medical and technical accuracy: Translations of clinical indications, contraindications, warnings, and device performance specifications must be medically and technically accurate. Errors in these areas are not just a regulatory problem — they create patient safety risks and potential liability.
• Consistency across documents: All Korean-language documents in a submission must use consistent terminology. If the device description uses one Korean term for a component and the IFU uses a different term, MFDS reviewers will flag this as a deficiency.
• Back-translation verification: For critical documents (particularly clinical sections, warnings, and contraindications), best practice is to have the Korean translation back-translated into English by a second translator, then reviewed by the manufacturer's regulatory team for accuracy. This adds time but catches errors that would otherwise trigger deficiency letters.
• MFDS reviewer expectations: MFDS reviewers read submissions in Korean. If the Korean text is awkward, ambiguous, or clearly machine-translated, it undermines confidence in the submission and invites additional scrutiny.

Product Labeling

All product labeling — including the device label, Instructions for Use (IFU), and packaging — must be in Korean. There is no exception for "professional use only" devices. The Korean labeling must include:

• Device name (in Korean)
• Intended use
• Manufacturer name and address
• Korean License Holder name and address
• Manufacturing date and/or expiration date
• Lot/serial number
• Storage and handling conditions
• Warnings and precautions
• Directions for use
• License (approval) number

The Korean Authorized Representative typically handles or coordinates the translation and formatting of Korean labeling. However, the manufacturer retains responsibility for the technical accuracy of the translated content.

Translation Timeline and Cost Planning

For a typical Class III device submission, the translation workload includes:

Document Category	Estimated Translation Time	Notes
Application forms and administrative documents	1–2 weeks	Relatively straightforward; templates available from KAR
Device description and technical summaries	2–3 weeks	Requires technical translator with device knowledge
Test data summaries	1–2 weeks	Key findings summaries for foreign test reports
Clinical data summaries	2–3 weeks	Most sensitive — clinical terminology must be precise
IFU and labeling	1–2 weeks	Must comply with MFDS labeling format requirements
Risk management summaries	1 week	ISO 14971 terminology in Korean
Total	4–8 weeks	Assumes sequential workflow; parallel translation reduces elapsed time

Translation costs for a full Class III submission package typically range from USD 5,000–15,000, depending on document volume and complexity. Budget for at least one round of revision after initial review by your Korean regulatory partner.

Practical tip: Do not treat Korean translation as a last-minute task. Poor translations — especially of clinical indications, contraindications, and warnings — trigger MFDS deficiency letters and can delay approval by weeks or months. Use translators who specialize in medical device regulatory content, and have the translated documents reviewed by your Korean regulatory partner before submission. Machine translation (including AI-based tools) should only be used for initial drafts — never submit machine-translated documents to MFDS without thorough human review by a qualified medical device regulatory translator.

IVD Registration Specifics

In vitro diagnostic (IVD) devices are regulated under the same Medical Devices Act as other medical devices in South Korea, but there are specific requirements and nuances that IVD manufacturers must understand.

IVD Classification

IVDs are classified into Class I through IV using the same risk-based framework, but with classification criteria specific to diagnostic purpose:

Class	IVD Examples
Class I	General laboratory reagents, sample preparation consumables, non-critical specimen containers
Class II	Clinical chemistry analyzers, hematology reagents, immunoassay systems for general diagnostics, culture media
Class III	Blood glucose monitoring systems, companion diagnostics, infectious disease tests (non-critical), tumor markers
Class IV	HIV/HBV/HCV screening tests (blood supply), blood grouping reagents (ABO, Rh), nucleic acid tests for transfusion screening

IVD-Specific Requirements

In addition to the standard medical device requirements, IVD submissions must include:

• Analytical performance data: Sensitivity, specificity, accuracy, precision (repeatability and reproducibility), linearity, measuring range, limit of detection, limit of quantitation, and interference studies
• Clinical performance data: Clinical sensitivity, clinical specificity, positive and negative predictive values, based on clinical samples from the intended population
• Reference material traceability: Documentation showing calibration traceability to international reference materials or methods (where applicable)
• Stability data: Real-time and accelerated stability studies demonstrating the claimed shelf life
• Specimen type validation: Performance data for each specimen type claimed in the IFU (e.g., serum, plasma, whole blood, urine)

Korean Reference Samples

For certain IVD categories — particularly those related to infectious disease screening and blood banking — MFDS may require that performance validation be conducted using Korean reference samples or panels provided by the Korea National Institute of Health (KNIH) or the Korean Red Cross. This is intended to ensure that the assay performs appropriately against pathogen strains and genetic variants prevalent in the Korean population.

Practical tip: IVD manufacturers should check early in the process whether MFDS requires performance validation with Korean-specific reference panels. Obtaining and testing with these panels adds time and must be factored into the submission timeline. For infectious disease assays in particular, Korean strain diversity may differ from what was included in your global validation studies.

MDSAP Acceptance in South Korea

South Korea is not a full MDSAP Official Member like the US (FDA), Canada (Health Canada), Australia (TGA), Brazil (ANVISA), and Japan (MHLW/PMDA). MFDS holds Affiliate Member status in the MDSAP program — a category that also includes Mexico, Argentina, Israel, Kenya, Taiwan, and South Africa. However, MFDS has established a recognition framework that allows MDSAP certificates to be used in support of KGMP compliance, formalized through the MDSAP Audit Results Utilization Guideline (Guide No. 1349-01, published February 2024).

Current Status

• MFDS recognizes MDSAP audit results as evidence of quality management system compliance
• An MDSAP certificate can replace or reduce the scope of a separate KGMP facility audit for foreign manufacturers — but only for initial certification, not renewals
• The degree of acceptance may vary by device class — Class III and IV devices may still be subject to supplemental MFDS review
• MFDS has participated in MDSAP observer activities and continues to deepen its integration with the program

Detailed MDSAP Acceptance Criteria

The specifics of MDSAP acceptance for KGMP purposes are important for planning:

Criterion	Requirement
Applicable audit type	Initial KGMP certification only. Renewal audits always require on-site inspection.
Report format	Must conform to MDSAP F0019.1 format. Reports in other formats or generated solely by the AO without the standard MDSAP format will be rejected.
Compliance record	No Grade 5 non-conformities permitted. Maximum one Grade 4 non-conformity in Section 12 of the MDSAP report.
Certificate validity	KGMP certificate validity will be aligned with the MDSAP certificate expiration date, not the standard 3-year KGMP cycle.
Auditing Organization	Must be an MDSAP-recognized AO. Currently recognized AOs include BSI, DEKRA, DNV, DQS Medizinprodukte, Intertek, G-MED, NSAI, SGS, TUV Rheinland, TUV SUD, TUV NORD, and UL Solutions.
Application fee	Standard KGMP application fee still applies even if MDSAP is accepted for a document-only review.

Practical Implications

For manufacturers that already hold MDSAP certificates (particularly those selling in Canada, where MDSAP is mandatory):

• You have a significant advantage in the Korean market because the KGMP audit — which is often the most time-consuming prerequisite for foreign manufacturers — can potentially be streamlined
• However, the practical success rate for obtaining a paper-based audit using MDSAP is approximately 50%. For manufacturers that have never undergone an MFDS audit, MFDS will almost certainly require an on-site audit as part of initial KGMP certification, regardless of MDSAP status. This typically involves a delegation of four Korean inspectors visiting the manufacturing facility.
• Discuss the specifics with your Korean Authorized Representative, as the acceptance process requires formal communication with MFDS and the appropriate documentation
• MDSAP certificates from recognized Auditing Organizations are most readily accepted; confirm your AO is on the MFDS-accepted list before relying on this pathway
• Plan for both scenarios: even if you pursue the MDSAP pathway, maintain readiness for a full on-site audit. Having a backup plan avoids a 3–6 month delay if MFDS declines the paper-based review

Registration Timeline and Fees

Understanding the total timeline and cost structure is essential for planning your Korean market entry.

Typical End-to-End Timelines

Activity	Estimated Timeline
Engage Korean Authorized Representative	1–2 months
Gap analysis and documentation preparation	2–4 months
Product testing (if new testing required)	2–6 months
KGMP audit (if required)	3–6 months (including scheduling lead time)
Clinical trial (if required)	12–24 months
MFDS submission preparation	1–2 months
MFDS review — Class I	2–4 weeks
MFDS review — Class II	3–6 months
MFDS review — Class III	6–10 months
MFDS review — Class IV	8–14 months
HIRA reimbursement listing (if applicable)	3–9 months after MFDS approval

Total time from project initiation to market for a typical Class III device without clinical trial requirement: 12–18 months. With a Korean clinical trial requirement, add 12–24 months.

Fee Structure

MFDS charges fees for device approval applications, KGMP audits, and other regulatory services. Fees are denominated in Korean Won (KRW).

Fee Category	Approximate Range (KRW)	Approximate USD Equivalent
Class I notification	30,000–50,000	$22–$37
Class II approval review	300,000–800,000	$220–$590
Class III approval review	500,000–1,200,000	$370–$880
Class IV approval review	800,000–1,500,000	$590–$1,100
KGMP facility audit (domestic)	500,000–2,000,000	$370–$1,470
KGMP facility audit (international)	3,000,000–8,000,000+	$2,200–$5,900+
Clinical trial application review	500,000–1,500,000	$370–$1,100

Note: International KGMP audit fees include auditor travel and accommodation costs, which can be substantial for facilities located far from South Korea. Fees are periodically updated by MFDS.

Practical tip: While MFDS fees are modest compared to FDA user fees, the total cost of Korean market entry is dominated by indirect costs: Korean Authorized Representative fees, translation costs, any required supplemental testing, clinical trials, and KGMP audit logistics. Budget the full cost picture, not just the government fees. A realistic budget for Class III device registration (without clinical trial) is USD 50,000–150,000 all-in, depending on the complexity of the device and the amount of supplemental work required.

Reimbursement: HIRA and Market Access

Obtaining MFDS approval is necessary but not sufficient for commercial success in South Korea. The vast majority of medical devices used in the Korean healthcare system are reimbursed through the National Health Insurance (NHI) system, administered by the Health Insurance Review and Assessment Service (HIRA) and the National Health Insurance Service (NHIS).

How Korean Reimbursement Works

South Korea has universal health coverage through a single-payer National Health Insurance system. Over 97% of the population is covered. Hospitals, clinics, and other healthcare providers bill NHIS for medical services and products, and NHIS pays based on fee schedules and reimbursement codes established by HIRA.

For medical devices, this means:

• If your device has a HIRA reimbursement code and price, hospitals can use it and get reimbursed. This is the pathway to significant volume.
• If your device does not have a reimbursement code, hospitals must absorb the cost themselves or pass it to patients. In practice, most hospitals will not adopt devices without reimbursement coverage, particularly for routine clinical use.

Generally, only implantable or disposable medical devices are reimbursed separately — examples include pacemakers, spinal fixation products, drug-eluting stents, orthopedic trauma products, and sutures. Capital equipment (e.g., imaging systems, surgical robots) is typically bundled into facility fees rather than reimbursed per-procedure.

The Three-Agency Evaluation Chain

A critical aspect of Korean medical device market access that many foreign manufacturers do not fully appreciate is that reimbursement involves not two but three government agencies, each with a distinct role:

1. MFDS (Ministry of Food and Drug Safety): Grants regulatory approval — confirming the device is safe and effective. This is the prerequisite for everything that follows.

2. NECA (National Evidence-based Healthcare Collaborating Agency): Conducts the New Health Technology Assessment (nHTA) for novel devices. NECA performs a systematic review evaluating the safety and effectiveness of new non-pharmaceutical technologies (including associated clinical procedures). NECA categorizes the technology to determine whether it is eligible for HIRA reimbursement review. Not all devices go through NECA — only those that represent genuinely new technologies. Devices with existing predicates in the NHI system typically bypass the NECA assessment.

3. HIRA (Health Insurance Review and Assessment Service): Makes the final reimbursement determination. The Medical Device Expert Evaluation Committee within HIRA reviews evidence — submitted by manufacturers, institutions, or societies — to assess the device's value for reimbursement. Based on this assessment and reference pricing, HIRA recommends a reimbursement price to the Ministry of Health and Welfare (MoHW).

Understanding which agencies your device will need to go through — and in what order — is essential for realistic timeline planning.

Reimbursement Process

Step	Description	Timeline
1. MFDS approval	Prerequisite — you cannot apply for reimbursement without a valid MFDS license	See above
2. HIRA application	All eligible devices must apply to HIRA for reimbursement within 30 days of product approval. Missing this window can create administrative complications.	Immediate post-approval
3. NECA new health technology assessment (if applicable)	For truly novel devices, NECA conducts a systematic review evaluating clinical safety and effectiveness. This determines whether the technology is eligible for reimbursement review by HIRA.	6–12 months
4. HIRA reimbursement review	HIRA's Medical Device Expert Evaluation Committee evaluates the device's value. Submission includes pricing proposal, clinical evidence, and cost-effectiveness data.	3–6 months
5. NHI reimbursement code and price assignment	HIRA assigns a code and recommends a reimbursement price to the Ministry of Health and Welfare	Included in HIRA review timeline
6. National Health Insurance Policy Deliberation Committee	Final approval of new reimbursement listings by MoHW	1–3 months

Pricing Considerations

HIRA uses several methods to determine medical device reimbursement prices:

• Predicate-based pricing (default method): Under Korea's regulations, medical devices are grouped with predicate devices and assigned the lowest price among existing predicates. This is the default pricing rule and is only avoidable if HIRA determines the product has significant clinical advantages, in which case it may receive the highest price among existing predicates. This default-to-lowest pricing policy is one of the most important commercial realities of the Korean market.
• Value Appraisal System: For devices that demonstrate meaningful clinical improvement over existing options, HIRA may apply a value appraisal, which allows for pricing above the predicate range. This requires robust clinical and health economic evidence demonstrating superiority — not just equivalence — compared to the current standard of care in Korea.
• Foreign reference pricing: HIRA considers prices in seven reference countries (including the US, UK, Germany, France, Italy, Japan, and Switzerland). If your device is priced significantly higher in Korea than in reference markets, HIRA will push back. Foreign reference pricing may result in adjustments either up or down from the initially proposed price.
• Cost-effectiveness evaluation: For novel or high-cost devices, HIRA may require formal cost-effectiveness analysis comparing your device to the standard of care. For premium pricing decisions, HIRA performs a multi-criteria decision analysis considering clinical evidence, pharmacoeconomic evidence, real-world evidence, and improvement potential.
• New device pricing: If the product is completely new with no predicates, HIRA will establish a new reimbursement price, but this will almost always be lower than the reimbursement price in advanced Western countries. This pricing dynamic has been a source of contention in US-Korea trade discussions and generally does not favor novel medical products.
• Revaluation System: HIRA periodically re-evaluates and adjusts the prices of listed medical devices, typically downward. The revaluation system aims to lower reimbursement levels for older devices, creating fiscal headroom for new technologies. Manufacturers should anticipate price erosion over time for mature products.

The practical result: medical device reimbursement prices in South Korea are generally lower than in the US and often lower than in Western Europe. Manufacturers must factor this into their commercial strategy and pricing model.

Non-Reimbursed and Patient-Pay Markets

Some device categories — particularly cosmetic and elective-use devices — operate outside the NHI reimbursement system. In these markets, pricing is determined by the manufacturer and distributor, and patients pay out of pocket. Examples include cosmetic laser devices, certain dental implants, and aesthetic products.

Practical tip: Start your HIRA reimbursement strategy in parallel with your MFDS approval process — not after. The reimbursement pathway adds 3–9 months post-approval, and delays in reimbursement listing directly delay revenue generation. Engage a Korean consultant or your distributor who understands HIRA pricing dynamics early, because your global pricing strategy may need to be adjusted for the Korean market.

Post-Market Requirements

MFDS post-market surveillance requirements have strengthened significantly in recent years, reflecting a global trend toward lifecycle regulatory oversight.

Adverse Event Reporting

Manufacturers (through their Korean License Holder) are required to report adverse events to MFDS:

Event Type	Reporting Timeline
Death or serious injury	Within 15 days of becoming aware
Malfunction with potential to cause death or serious injury	Within 15 days of becoming aware
Trend of events not individually reportable	Periodic reporting (typically within MFDS-specified timelines)

Post-Market Surveillance Activities

• Periodic Safety Update Reports: For Class III and IV devices, manufacturers must submit periodic safety update reports to MFDS at intervals specified in the approval conditions (typically every 1–3 years).
• Re-evaluation: MFDS can require device re-evaluation — a comprehensive review of safety and performance data — if new concerns emerge post-market. This can include a review of global adverse event data, new clinical literature, and updated risk-benefit analysis.
• Field Safety Corrective Actions (FSCA): If a product defect or safety issue is identified, the manufacturer must implement corrective actions (recall, advisory notice, product modification) and notify MFDS. Korean recall classifications and procedures are similar to the FDA's recall framework.
• Tracking requirements: For certain high-risk implantable devices, MFDS may require device tracking — maintaining records that allow individual devices to be traced from manufacturer to patient.

License Renewal and Maintenance

MFDS licenses are not indefinite. Key maintenance obligations include:

• License renewal: Some device licenses require periodic renewal (the specific requirements depend on the device class and approval conditions)
• Change notifications: Any change to the device design, manufacturing process, intended use, labeling, or manufacturing site must be reported to MFDS. Depending on the significance of the change, this may require a new approval application, a supplemental application, or a simple notification.
• Annual license maintenance: The Korean License Holder must maintain the license in good standing, which includes keeping the KGMP certification current and fulfilling all post-market obligations.

Recent Regulatory Reforms

South Korea's medical device regulatory system has undergone significant modernization in recent years. These reforms are designed to accelerate innovation, improve international harmonization, and strengthen post-market safety. The pace of reform has accelerated markedly since 2024, with several landmark changes taking effect in 2025 and 2026.

Digital Medical Products Act (Effective January 24, 2025)

The most significant recent reform is the Digital Medical Products Act, which entered into force on January 24, 2025. This is a standalone law — separate from the Medical Devices Act and the In Vitro Diagnostic Medical Devices Act — that creates a dedicated regulatory framework for digital medical products.

The Act covers three categories:

1. Digital medical devices — software and AI-based products that meet the definition of a medical device
2. Digital medical/health support devices — products that support health management but may not rise to the level of medical devices
3. Drug-digital combinations — pharmaceuticals combined with digital medical devices or digital health support devices

Key implications for manufacturers:

• SaMD and other digital medical devices remain subject to the Medical Devices Act where the Digital Medical Products Act does not have corresponding provisions — manufacturers must navigate both laws simultaneously.
• New labeling requirements specific to digital medical device software took effect on January 24, 2026 (Article 22 of the Act).
• Requirements for digital medical/health support devices (Articles 33–35) also took effect January 24, 2026.
• The Act requires those who intend to manufacture or import digital medical products to obtain authorization from MFDS, similar to the traditional medical device authorization process.

MFDS Classification Reform for Digital Products (2026)

In conjunction with the Digital Medical Products Act, MFDS revised the Regulations on Classification and Designation of Digital Medical Products in 2026. This revision formally distinguishes digital medical products from digital health support products, creating clearer boundaries between regulated medical devices and lower-risk wellness technologies.

Key elements:

• MFDS now evaluates intended use statements, user manuals, app store descriptions, corporate websites, advertising campaigns, and partner communications to determine whether a product falls within medical device regulation.
• Developers of wellness-focused products may benefit from streamlined regulatory pathways when their products clearly fall outside medical intended use — but this requires careful attention to product design, labeling, and marketing materials.

Transfer of Class II Review to NIDS (2026)

MFDS has transferred Class II device equivalence confirmation procedures from MFDS headquarters to the National Institute of Medical Device Safety Information (NIDS). NIDS, a legal entity established under the Medical Devices Act in 2012, now handles:

• Technical document review for all Class II medical devices (through eight designated third-party review agencies that report to NIDS)
• Registration of Class I devices through the MFDS portal
• Support and information services for clinical investigations, standards, safety, and training

This centralization means that for Class II devices, the regulatory relationship is primarily with NIDS and its designated review agencies — not with MFDS headquarters directly. Class III and IV devices still go through MFDS headquarters for review and approval.

2026 KGMP Framework Overhaul

MFDS formally published updated Medical Device GMP Regulations in February 2026, representing a significant overhaul organized into four pillars:

1. Enforcement Rule of the Medical Devices Act — foundational law governing classification, business approvals, and quality manager qualifications
2. General Standards for Good Manufacturing Practice — standard requirements for traditional medical hardware
3. GMP for In Vitro Diagnostic (IVD) Medical Devices — specialized standards for diagnostic reagents and equipment
4. GMP for Digital Medical Devices — a new module dedicated to medical software and AI-enabled technologies

The phased enforcement timeline:

Effective Date	Requirement
April 21, 2025	Mandatory use of the Digital Medical Device GMP module for software and AI-based products
August 12, 2025	Updated standards for In Vitro Diagnostics
October 31, 2025	Formal enforcement of the overarching Medical Devices Act Enforcement Rules
December 9, 2025	Deadline for compliance with the updated General Manufacturing Standards

Key changes in the 2026 framework:

• AI Control Assessment: For the first time, standalone software and AI-enabled devices have a dedicated GMP path. Manufacturers must pass an "AI Control" assessment evaluating algorithm transparency, data de-identification, and cybersecurity measures.
• Quality Manager requirements: Every manufacturing site must assign at least one Quality Manager meeting specific educational and experience criteria. Quality Managers are now required to complete 8 hours of mandatory annual training to maintain their certification.
• Post-market surveillance integration: MFDS now expects manufacturers to demonstrate that post-market surveillance (PMS) data feeds back into manufacturing quality controls. The new PMS module requires periodic safety reporting every 6 months in the first year of a product's launch. High-risk and implantable devices are subject to additional reporting requirements.

Cybersecurity Requirements for Connected Devices (2026)

The January 2026 amendment to the Regulation on Permission, Notification, Review of Medical Devices introduced mandatory cybersecurity documentation for devices utilizing wired or wireless communication. Manufacturers must now include:

• Cybersecurity-related information within the technical documentation, specifically in the Shape and Structure section and the Precautions for Use section
• Supporting materials demonstrating the implementation of cybersecurity controls, including threat modeling, vulnerability management, and incident response capabilities

This requirement applies to all connected devices regardless of class and aligns Korea with the global trend toward mandatory cybersecurity requirements for medical devices.

Expanded Clinical Evidence Acceptance (2026)

The January 2026 amendment also expanded the types of clinical evidence MFDS accepts for regulatory submissions. In addition to clinical trial data from MFDS-designated institutions, MFDS now explicitly accepts:

• Reliable overseas clinical data compliant with Korean Good Clinical Practice
• Clinical trial data reviewed by regulatory authorities in OECD member countries
• Publications from SCI or SCIE-indexed journals
• Clinical Evaluation Reports (CERs) — aligning more closely with the EU MDR approach to clinical evidence

This is a meaningful liberalization that reduces the burden on foreign manufacturers, particularly those with robust clinical evidence from other major jurisdictions.

Innovative Medical Device Designation Updates

The innovative medical device program has been significantly expanded:

• Devices based on entirely new principles or intended uses must obtain approval based on clinical trial data and are subject to post-market surveillance for 4 to 7 years after approval.
• These devices are now eligible for priority review, providing faster access to market.
• Equivalence-based applications referencing innovative Class III or IV devices may be restricted during the post-market surveillance period — preventing fast-follow competitors from using the innovative device as a predicate until sufficient post-market data has been collected.
• Additional incentives include regulatory fee waivers, accelerated review timelines, and dedicated MFDS consultation support.

Accelerated Reimbursement Pathways for Innovative Technologies

South Korea has introduced special pathways to accelerate patient access to new medical technologies:

• Parallel review pathways: MFDS regulatory review and HIRA reimbursement assessment can proceed simultaneously for eligible devices, rather than sequentially. This can save 6–12 months compared to the traditional sequential approach.
• Conditional approval for evidence development: Devices can receive conditional approval with time-limited uninsured (out-of-pocket) clinical use, during which additional evidence is collected. After a defined period (typically 3 years), a full NECA assessment determines reimbursement eligibility.
• Rapid assessment for IVDs and genetic tests: Streamlined NECA assessment for certain diagnostic technologies with clear clinical utility.

Other Key Recent Developments

Increased Acceptance of Foreign Data (2022–2026): MFDS has progressively expanded the types of foreign regulatory data it accepts, including foreign clinical trial data, test reports from ILAC MRA-accredited laboratories, and FDA/CE approval summaries as supporting evidence. This reflects MFDS's broader goal of reducing redundant requirements that delay access to safe, effective devices without adding meaningful safety benefit.

Digital Health and AI-Based Devices: South Korea has been at the forefront of regulating AI-based medical devices. MFDS has approved a significant number of AI-based devices — particularly in diagnostic imaging (radiology, pathology, ophthalmology) — making it one of the most active regulators globally for AI medical device approvals. As of October 2025, 16 AI-based technologies in radiology alone are in clinical use through various regulatory pathways. MFDS published guidance on AI medical device evaluation that covers algorithm validation, dataset requirements, continuous learning models, and clinical performance evaluation.

Post-Market Surveillance Strengthening (2024–2025): MFDS has increased post-market surveillance requirements for Class III and IV devices, including more frequent periodic safety reporting, expanded scope of re-evaluation authority, and enhanced adverse event reporting systems.

Mutual Recognition Agreements: South Korea has signed or is negotiating mutual recognition arrangements with several countries and regions for medical device GMP inspections and, in some cases, product approvals. The MDSAP recognition discussed earlier is one example. MFDS has also strengthened bilateral cooperation with FDA, PMDA (Japan), and TGA (Australia).

MFDS Approval Validity: Class II, III, and IV device approvals are now valid for 5 years and must be renewed. This is a change from the previous system where some approvals had indefinite validity.

Regulatory Convergence Efforts

MFDS is an active participant in the International Medical Device Regulators Forum (IMDRF) and the Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum. Through these bodies, MFDS has contributed to international convergence in areas including UDI, adverse event terminology, SaMD classification, and clinical evidence requirements. The practical impact for manufacturers is a gradual reduction in Korea-specific requirements that diverge from international standards — though this convergence is incremental, not immediate.

South Korea vs. FDA vs. EU: A Detailed Comparison

Understanding how the Korean system compares to the FDA and EU MDR frameworks helps manufacturers leverage existing regulatory work and identify Korea-specific gaps.

Factor	South Korea (MFDS)	United States (FDA)	European Union (EU MDR)
Regulatory authority	MFDS (government ministry)	FDA (government agency)	Notified Bodies (private, designated by EU member states) under Competent Authority oversight
Classification	4 classes (I–IV)	3 classes (I–III)	4 classes (I, IIa, IIb, III)
Highest risk class	Class IV	Class III	Class III
Pre-market pathway (low risk)	Class I: Notification	Class I: Mostly exempt; some require 510(k)	Class I: Self-declaration
Pre-market pathway (moderate risk)	Class II/III: Technical review and approval	Class II: 510(k)	Class IIa/IIb: Notified Body conformity assessment
Pre-market pathway (high risk)	Class IV: Technical review and approval (most rigorous)	Class III: PMA	Class III: Notified Body conformity assessment
GMP/QMS requirement	KGMP (based on ISO 13485 + Korea additions)	QMSR (based on ISO 13485, effective Feb 2026)	ISO 13485 + EU MDR Annex IX
GMP audit for foreign manufacturers	MFDS audit or MDSAP acceptance	FDA inspection or MDSAP acceptance	Notified Body audit
Clinical data for highest risk	Usually required; Korean clinical trial may be required	PMA requires clinical data (US IDE trials common)	Clinical evaluation mandatory; clinical investigation often required for Class III
Authorized Representative	Korean License Holder required for imports	US Agent required for foreign establishments; no approval held by agent	EU Authorized Representative required for non-EU manufacturers
Language	Korean (all submissions and labeling)	English	Language of the member state where marketed (labeling); English accepted by many NBs for technical files
Review body	MFDS (Class III/IV), NIDS-designated reviewers (Class II), KTR (testing)	FDA (government)	Notified Body (private third party)
Typical Class III/IV review time	6–14 months	510(k): 3–6 months; PMA: 12–18 months	6–18 months (varies significantly by Notified Body)
Reimbursement	HIRA (separate application after MFDS approval)	CMS, private payers (separate from FDA clearance)	Member state-level HTA and reimbursement (varies by country)
Post-market surveillance	Adverse event reporting, periodic safety reports, re-evaluation	MDR (medical device reporting), corrections/removals	PMS plan, PMCF, PSUR, vigilance reporting
UDI	Korean UDI system being implemented (aligned with IMDRF)	FDA UDI (mandatory, phased by class)	EU UDI (mandatory, phased by class)
MDSAP recognition	Affiliate member (partial acceptance for initial KGMP)	Full member (voluntary)	Not a participant

Tips for Foreign Manufacturers

Based on common challenges and best practices observed across hundreds of Korean device registrations, here are the most important considerations for foreign manufacturers entering the South Korean market.

1. Start with the Right Korean Partner

Your Korean Authorized Representative or distributor is your single most important relationship in the Korean market. They will navigate MFDS on your behalf, manage translations, coordinate testing, and handle post-market obligations. Choose a partner with:

• Demonstrated experience registering devices in your product category
• Direct relationships with MFDS reviewers and KTR testing staff
• Transparent fee structures and clear communication practices
• Willingness to address license ownership and transfer rights contractually

2. Do Not Assume FDA or CE Equivalence

The most expensive mistake foreign manufacturers make is assuming their FDA 510(k) or CE marking dossier can be submitted to MFDS with minimal modification. While MFDS increasingly accepts foreign data, the submission format, required documentation, Korean-language requirements, and specific technical standards differ. A proper gap analysis — comparing your existing dossier against MFDS requirements item by item — is always the right first step.

3. Address KGMP Early

The KGMP audit or MDSAP recognition process is often the longest lead-time item for foreign manufacturers. If you do not already have an MDSAP certificate or a current KGMP certificate, start this process at least 6 months before you plan to submit your device application. A device application cannot be approved without KGMP compliance evidence.

4. Plan for Translation Time and Cost

Every primary submission document must be in Korean. Technical translation of medical device regulatory documents is specialized work, and poor translations are a leading cause of deficiency letters. Budget 4–8 weeks for translation and review of a typical Class III submission package.

5. Engage MFDS Early for Novel Devices

MFDS offers pre-submission consultations for novel or complex devices. These meetings can clarify classification, testing requirements, clinical data expectations, and any Korea-specific requirements before you invest in preparing a full submission. This is especially valuable for Class III/IV devices, AI-based devices, and combination products.

6. Build Korean Clinical Trial Capability into Your Global Strategy

If there is any possibility that MFDS will require Korean clinical data, design your global clinical program to include Korean sites from the start. Adding Korean sites to a global trial after the fact is far more expensive and time-consuming than including them in the original protocol.

7. Plan for Reimbursement Concurrently

Do not wait for MFDS approval to begin your reimbursement strategy. Understand the HIRA pricing landscape for your product category, identify comparable devices and their reimbursement codes and prices, and prepare your health economic value proposition. The 3–9 months between MFDS approval and HIRA reimbursement listing represents dead time when you have market authorization but limited commercial traction.

8. Monitor Regulatory Changes

MFDS is an active, evolving regulator. Regulatory requirements, fee schedules, testing standards, and acceptance criteria for foreign data change regularly. Your Korean Authorized Representative should be monitoring these changes and advising you proactively. If they are not, that is a red flag.

9. Understand the Cultural and Business Context

South Korea's business culture values relationships, consistency, and attention to detail. MFDS reviewers are thorough and expect complete, well-organized submissions. Responding to deficiency letters promptly and comprehensively — rather than providing partial responses — builds credibility and can improve review outcomes. Your Korean partner can advise on communication norms and reviewer expectations.

10. Consider the Broader Asia-Pacific Strategy

South Korea is often a gateway to the broader Asia-Pacific market. Korean MFDS approval, combined with Japanese PMDA approval, covers the two largest regulated medical device markets in Asia. Some manufacturers use their Korean clinical data and regulatory documentation to support submissions in other Asian markets (e.g., Taiwan TFDA, ASEAN member states). Consider how your Korean registration fits into your overall Asia-Pacific regulatory strategy.

Conclusion

South Korea offers a large, sophisticated, and growing market for medical device companies — but it demands a dedicated regulatory strategy. The MFDS framework is well-structured, increasingly aligned with international standards, and administered by a competent regulatory authority that is investing in modernization.

The keys to success are straightforward: choose the right Korean partner, understand the classification and approval pathway for your specific device, address KGMP compliance early, invest in quality translations, plan for clinical data requirements proactively, and start your reimbursement strategy before you have MFDS approval in hand.

Manufacturers who treat South Korea as an afterthought — tacking it onto a US or EU regulatory plan without dedicated attention — consistently underperform on timelines and costs. Those who invest in understanding the system and building the right Korean relationships find a market that rewards quality products with strong commercial potential.